Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Basal insulin initiation in primary vs. specialist care: similar glycaemic control in two different patient populations.

Orozco-Beltran D, Pan C, Svendsen AL, Faerch L, Caputo S; SOLVE Study Group.

Int J Clin Pract. 2016 Mar;70(3):236-43. doi: 10.1111/ijcp.12776. Epub 2016 Feb 24.

2.

The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.

von Scholten BJ, Ørsted DD, Svendsen AL, Persson F, Rossing P.

J Diabetes Complications. 2015 Nov-Dec;29(8):1146-51. doi: 10.1016/j.jdiacomp.2015.08.007. Epub 2015 Aug 13.

PMID:
26345339
3.

The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.

Brunner M, Pieber T, Korsatko S, Kojzar H, Svendsen AL, Haahr H.

Drugs Aging. 2015 Jul;32(7):583-90. doi: 10.1007/s40266-015-0272-y.

4.

Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.

Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H.

Diabetes Obes Metab. 2015 Jul;17(7):659-64. doi: 10.1111/dom.12463. Epub 2015 May 1.

PMID:
25772444
5.

Depressive symptoms prior to and following insulin initiation in patients with type 2 diabetes mellitus: Prevalence, risk factors and effect on physician resource utilisation.

Dzida G, Karnieli E, Svendsen AL, Sølje KS, Hermanns N; SOLVE Study Group.

Prim Care Diabetes. 2015 Oct;9(5):346-53. doi: 10.1016/j.pcd.2015.01.002. Epub 2015 Jan 30.

7.

Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study.

Yale JF, Damci T, Kaiser M, Karnieli E, Khunti K, Liebl A, Baeres FM, Svendsen AL, Ross SA; SOLVE Study Group.

Diabetol Metab Syndr. 2013 Oct 2;5(1):56. doi: 10.1186/1758-5996-5-56.

8.

Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.

Vora J, Caputo S, Damci T, Orozco-Beltran D, Pan C, Svendsen AL, Sølje KS, Khunti K; SOLVE study group.

J Clin Pharm Ther. 2014 Apr;39(2):136-43. doi: 10.1111/jcpt.12116. Epub 2013 Dec 13.

PMID:
24329524
9.

Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.

Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL; SOLVE Study Group.

J Diabetes. 2014 May;6(3):243-50. doi: 10.1111/1753-0407.12091. Epub 2013 Oct 29.

10.

Resource utilisation and quality of life following initiation of insulin detemir in patients with type 2 diabetes mellitus.

Liebl A, Andersen H, Svendsen AL, Vora J, Yale JF; SOLVE Study Group.

Int J Clin Pract. 2013 Aug;67(8):740-9. doi: 10.1111/ijcp.12133.

PMID:
23869677
11.

Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus.

Heller S, Bode B, Kozlovski P, Svendsen AL.

J Diabetes. 2013 Dec;5(4):482-91. doi: 10.1111/1753-0407.12060. Epub 2013 May 7.

12.

Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).

Karnieli E, Baeres FM, Dzida G, Ji Q, Ligthelm R, Ross S, Svendsen AL, Yale JF; SOLVE Study Group.

Drugs Aging. 2013 Mar;30(3):167-75. doi: 10.1007/s40266-013-0054-3.

13.

Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice.

Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini LF, Svendsen AL; SOLVE Study Group.

Endocr Pract. 2013 May-Jun;19(3):462-70. doi: 10.4158/EP12269.OR.

PMID:
23337147
14.

The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.

Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF; SOLVE Study Group.

Diabetes Obes Metab. 2012 Dec;14(12):1129-36. doi: 10.1111/j.1463-1326.2012.01665.x. Epub 2012 Aug 30.

PMID:
22830956
15.
16.

Hormonal contraception and risk of venous thromboembolism: national follow-up study.

Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C.

BMJ. 2009 Aug 13;339:b2890. doi: 10.1136/bmj.b2890.

17.

Risk factors for respiratory syncytial virus hospitalisation in children with heart disease.

Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Kongstad T, Svendsen AL, Nielsen BW.

Arch Dis Child. 2009 Oct;94(10):785-9. doi: 10.1136/adc.2008.143057. Epub 2009 Jun 18.

PMID:
19541682
18.

Induced abortions in Danish cancer survivors: a population-based cohort study.

Winther JF, Boice JD Jr, Svendsen AL, Frederiksen K, Olsen JH.

J Natl Cancer Inst. 2009 May 6;101(9):687-9. doi: 10.1093/jnci/djp064. Epub 2009 Apr 28.

19.

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R; Nordic Society for Paediatric Haematology and Oncology.

Blood. 2009 Jun 11;113(24):6077-84. doi: 10.1182/blood-2008-11-187880. Epub 2009 Feb 17.

20.

Spontaneous abortion in a Danish population-based cohort of childhood cancer survivors.

Winther JF, Boice JD Jr, Svendsen AL, Frederiksen K, Stovall M, Olsen JH.

J Clin Oncol. 2008 Sep 10;26(26):4340-6. doi: 10.1200/JCO.2007.15.2884. Erratum in: J Clin Oncol. 2008 Nov 20;26(33):5493.

21.

Time trends in the incidence of acute lymphoblastic leukemia among children 1976-2002: a population-based Nordic study.

Svendsen AL, Feychting M, Klaeboe L, Langmark F, Schüz J.

J Pediatr. 2007 Nov;151(5):548-50.

PMID:
17961705
22.

Sexual habits before multiple sclerosis: a national case-control study.

Lidegaard Ø, Svendsen AL.

Mult Scler. 2008 Jan;14(1):67-72. Epub 2007 Sep 24.

PMID:
17893111
23.

Exposure to magnetic fields and survival after diagnosis of childhood leukemia: a German cohort study.

Svendsen AL, Weihkopf T, Kaatsch P, Schüz J.

Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1167-71.

24.

Nighttime exposure to electromagnetic fields and childhood leukemia: an extended pooled analysis.

Schüz J, Svendsen AL, Linet MS, McBride ML, Roman E, Feychting M, Kheifets L, Lightfoot T, Mezei G, Simpson J, Ahlbom A.

Am J Epidemiol. 2007 Aug 1;166(3):263-9. Epub 2007 May 7.

PMID:
17485729
25.

Breast cancer incidence after the introduction of mammography screening: what should be expected?

Svendsen AL, Olsen AH, von Euler-Chelpin M, Lynge E.

Cancer. 2006 May 1;106(9):1883-90.

26.

Development in incidence of breast cancer in non-screened Danish women, 1973-2002--a population-based study.

Fuglede N, Langballe O, Svendsen AL, Tjønneland A, Dalton SO, Johansen C.

Int J Cancer. 2006 May 1;118(9):2366-9.

Supplemental Content

Loading ...
Support Center